KITE-197
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
December 26, 2024
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
(clinicaltrials.gov)
- P=N/A | N=1000 | Enrolling by invitation | Sponsor: Kite, A Gilead Company | N=700 ➔ 1000
Enrollment change • Hematological Disorders • Hematological Malignancies • Oncology
July 22, 2024
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Active, not recruiting ➔ Recruiting
Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
June 07, 2024
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Active, not recruiting | Sponsor: Kite, A Gilead Company | Recruiting ➔ Active, not recruiting
Enrollment closed • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
March 29, 2024
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Trial primary completion date: Mar 2025 ➔ Dec 2027
Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
December 01, 2023
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company
Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
November 15, 2023
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Recruiting | Sponsor: Kite, A Gilead Company | Not yet recruiting ➔ Recruiting
Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
October 12, 2023
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
(clinicaltrials.gov)
- P1 | N=39 | Not yet recruiting | Sponsor: Kite, A Gilead Company
New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 7
Of
7
Go to page
1